Drug · CHEMBL113
Comparisons in its trials35
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
1 to 20 of 35
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Caffeine vs Placebo: serious adverse events | 0 of 103 | 0 of 102 | 205 | NCT02461693 | Trial comparisons |
| Paracetamol/Caffeine Tablet vs Paracetamol Powder: serious adverse events | 0 of 71 | 0 of 71 | 142 | NCT01466348 | Trial comparisons |
| CPC Adminstration vs Placebo Administration: deaths from any cause | 0 of 66 | 0 of 63 | 129 | NCT04972123 | Trial comparisons |
| CPC Adminstration vs Placebo Administration: serious adverse events | 0 of 66 | 0 of 63 | 129 | NCT04972123 | Trial comparisons |
| Caffeine vs Placebo: Occurence of Post Extubatory Respiratory Adverse Events. | 17 of 36 | 34 of 36 | 72 | NCT00273754 | Trial comparisons |
| Caffeine vs Placebo: Number of Children Who Developed Postextubation Adverse Respiratory Events Compared to Placebo. | 11 of 36 | 21 of 36 | 72 | NCT00273754 | Trial comparisons |
| Caffeine vs Placebo: serious adverse events | 0 of 36 | 0 of 36 | 72 | NCT00273754 | Trial comparisons |
| Reference Product vs Test Product: serious adverse events | 0 of 36 | 0 of 36 | 72 | NCT02629354 | Trial comparisons |
| Experimental vs Control: deaths from any cause | 0 of 33 | 0 of 31 | 64 | NCT03577730 | Trial comparisons |
| Experimental vs Control: serious adverse events | 2 of 33 | 4 of 31 | 64 | NCT03577730 | Trial comparisons |
| Experimental vs Control: Percentage of Delirious Patients Per Group | 7 of 30 | 14 of 30 | 60 | NCT03577730 | Trial comparisons |
| CPC Administration vs Placebo Administration: Percentage of Patients Who Have Asystolic Pauses > 3 Seconds in the CPC and Placebo Arms | 2 of 32 | 1 of 27 | 59 | NCT04972123 | Trial comparisons |
| Experimental vs Control: Number of Participants With Anxiety as Assessed by the Hospitalized Anxiety and Depression Scale (HADS-A) | 2 of 28 | 2 of 27 | 55 | NCT03577730 | Trial comparisons |
| Experimental vs Control: Number of Participants With Depression as Assessed by the Hospitalized Anxiety and Depression Scale (HADS-D) | 2 of 28 | 1 of 27 | 55 | NCT03577730 | Trial comparisons |
| Caffeine Arm vs Placebo Arm: deaths from any cause | 0 of 24 | 0 of 27 | 51 | NCT04950660 | Trial comparisons |
| Caffeine Arm vs Placebo Arm: serious adverse events | 0 of 24 | 0 of 27 | 51 | NCT04950660 | Trial comparisons |
| Caffeine vs Placebo: serious adverse events | 0 of 18 | 0 of 20 | 38 | NCT00879775 | Trial comparisons |
| D-amphetamine vs Caffeine Pills: serious adverse events | 0 of 12 | 0 of 12 | 24 | NCT00363298 | Trial comparisons |
| Early Caffeine vs Routine Caffeine: Intubation | 3 of 11 | 7 of 10 | 21 | NCT01783561 | Trial comparisons |
| Early Caffeine vs Routine Caffeine: Subjects Requiring Inotropes in the First 24 Hours | 0 of 11 | 2 of 10 | 21 | NCT01783561 | Trial comparisons |
pipelines-2026-09-18-0.3.1
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL113/comparisons